Clinical studies have shown beneficial cardiorenal effects of sotagliflozin in type 2 diabetes [8].Additionally, compared to pure SGLT2 inhibitors, dual SGLT1/2 inhibitors demonstrated lower myocardial infarction risk in diabetic patients [9]. The gene discussed is SLC5A2; the disease is myocardial infarction.